142 related articles for article (PubMed ID: 33709789)
1. Polymorphism of
Yang Y; Jia J; Sun Z; Liu C; Li Z; Xiao Y; Yu J; Du F; Shi Y; Sun J; Shui J; Zhang X
Future Oncol; 2021 Jun; 17(18):2351-2363. PubMed ID: 33709789
[TBL] [Abstract][Full Text] [Related]
2. Association between polymorphisms of ABCB1 and prognosis in esophageal squamous cell carcinoma patients treated with taxane.
Sun Z; Yang X; Du F; Shi Y; Sun J; Jia J; Liu C; Xiao Y; Yu J; Zhang X; Yang Y
J Gene Med; 2022 Jul; 24(7):e3434. PubMed ID: 35662334
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.
Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Matsumura S; Iwahashi M; Yamaue H
Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 26725778
[TBL] [Abstract][Full Text] [Related]
4. ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.
Nomura H; Tsuji D; Demachi K; Mochizuki N; Matsuzawa H; Yano T; Daiko H; Fujii S; Kojima T; Itoh K; Kawasaki T
Cancer Chemother Pharmacol; 2020 Aug; 86(2):315-324. PubMed ID: 32748110
[TBL] [Abstract][Full Text] [Related]
5. [Clinical evaluation of DLF, CLF and DFM regimens based on platinum compound plus 5-fluorouracil for treatment of advanced esophageal carcinoma].
Jiang Y; Qiu XH; Yang YX; Zhang SQ; Chen ZM
Ai Zheng; 2006 Aug; 25(8):1029-34. PubMed ID: 16965688
[TBL] [Abstract][Full Text] [Related]
6. A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.
Wang HY; Yao ZH; Tang H; Zhao Y; Jin SL; Zhou WP; Yao SN; Yang SJ; Liu YY; Luo SX
Oncotarget; 2017 Jan; 8(5):7540-7547. PubMed ID: 27902478
[TBL] [Abstract][Full Text] [Related]
7. Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
Kajiura S; Hosokawa A; Yoshita H; Ueda Y; Ueda A; Mihara H; Ando T; Fujinami H; Nishikawa J; Ogawa K; Minemura M; Sugiyama T
Am J Clin Oncol; 2016 Feb; 39(1):13-7. PubMed ID: 24322336
[TBL] [Abstract][Full Text] [Related]
8. THRB genetic polymorphisms can predict severe myelotoxicity after definitive chemoradiotherapy in patients with esophageal squamous cell carcinoma.
Miki I; Nakamura T; Kuwahara A; Yamamori M; Nishiguchi K; Tamura T; Okuno T; Omatsu H; Mizuno S; Hirai M; Azuma T; Sakaeda T
Int J Med Sci; 2012; 9(9):748-56. PubMed ID: 23136537
[TBL] [Abstract][Full Text] [Related]
9. Dysphagia Score as a Predictor of Adverse Events Due to Triplet Chemotherapy and Oncological Outcomes in 434 Consecutive Patients with Esophageal Cancer.
Hagi T; Makino T; Yamasaki M; Tanaka K; Nishida N; Sakai D; Motoori M; Kimura Y; Satoh T; Mori M; Doki Y
Ann Surg Oncol; 2019 Dec; 26(13):4754-4764. PubMed ID: 31452051
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma.
Miyawaki Y; Nakajima Y; Kawada K; Okada T; Tokairin Y; Kawano T
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27001629
[TBL] [Abstract][Full Text] [Related]
11. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
[TBL] [Abstract][Full Text] [Related]
12. Real-world outcomes with second-line therapy in advanced esophageal squamous cell carcinoma using SEER-Medicare data.
Danese M; Gricar J; Abraham P
Future Oncol; 2022 Mar; 18(8):927-936. PubMed ID: 35081734
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma.
Tanaka Y; Yoshida K; Yamada A; Tanahashi T; Okumura N; Matsuhashi N; Yamaguchi K; Miyazaki T
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1143-52. PubMed ID: 26896963
[TBL] [Abstract][Full Text] [Related]
14. Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer.
Okamoto H; Taniyama Y; Sakurai T; Heishi T; Teshima J; Sato C; Maruyama S; Ito K; Onodera Y; Konno-Kumagai T; Ishida H; Kamei T
Esophagus; 2018 Oct; 15(4):281-285. PubMed ID: 29948480
[TBL] [Abstract][Full Text] [Related]
15. [Phase II multicenter clinical trial of nedaplatin in the treatment of malignant tumors].
Zhang P; Feng FY; Wu LY; Hu Y; Liu JW; Gao YJ; Guan XQ; Nan KJ; Suo AL; Wang XW; Zhang MH; Zhang WD; Li CW; Zhang Y; Zhao JB
Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):230-4. PubMed ID: 16875614
[TBL] [Abstract][Full Text] [Related]
16. Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel.
Abraham JE; Guo Q; Dorling L; Tyrer J; Ingle S; Hardy R; Vallier AL; Hiller L; Burns R; Jones L; Bowden SJ; Dunn JA; Poole CJ; Caldas C; Pharoah PP; Earl HM
Clin Cancer Res; 2014 May; 20(9):2466-75. PubMed ID: 24599932
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.
Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Kato T; Kitadani J; Tabata H; Takeuchi A; Iwahashi M; Yamaue H
Anticancer Res; 2016 Feb; 36(2):829-34. PubMed ID: 26851048
[TBL] [Abstract][Full Text] [Related]
18. Genetic and epigenetic aberrations of ABCB1 synergistically boost the acquisition of taxane resistance in esophageal squamous cancer cells.
Sumarpo A; Ito K; Saiki Y; Ishizawa K; Wang R; Chen N; Sunamura M; Horii A
Biochem Biophys Res Commun; 2020 Jun; 526(3):586-591. PubMed ID: 32247608
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
[TBL] [Abstract][Full Text] [Related]
20. Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E).
Yamamoto S; Kato K; Daiko H; Kojima T; Hara H; Abe T; Tsubosa Y; Nagashima K; Aoki K; Mizoguchi Y; Kitano S; Yachida S; Shiba S; Kitagawa Y
Future Oncol; 2020 Jul; 16(19):1351-1357. PubMed ID: 32396014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
